SEC Form 4 · accession 0001813798-26-000019
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jim Wassil
Officer — EVP, Chief Scientific Ofc, COO
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 5:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 4, 2026 | S | 1,381 | $61.16 | D | 152,228 | D | |
| Common StockF3 | Sep 8, 2026 | F | 5,459 | $60.36 | D | 146,769 | D | |
| Common StockF4 | Sep 9, 2026 | S | 1,334 | $59.521 | D | 145,435 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F2The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
- F4The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.